Year Published
- 2008 (0)
- 2009 (7) Apply 2009 filter
- 2010 (5) Apply 2010 filter
- 2011 (1) Apply 2011 filter
- 2012 (0)
- 2013 (1) Apply 2013 filter
- 2014 (0)
- (-) Remove 2015 filter 2015
- 2016 (3) Apply 2016 filter
- 2017 (5) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
Types of Research
- Data Analysis (0)
- Literature Review (4) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (0)
- (-) Remove Global filter Global
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- Southern Africa Region and Selected Countries (0)
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove 2018 filter 2018
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove 2015 filter 2015
- (-) Remove Technology filter Technology
- (-) Remove Global filter Global
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
We review the status and characteristics of 48 national identity programs and initiatives in 43 developing countries, and evaluate how these programs are being connected to—or used for—service provision. The identity programs we review are mainly government-issued national IDs. However, we also review other types of national identity programs with links to various services including voter cards, passports, and two programs targeting the poor and the banking population. Following a brief review of the roles of identity systems in development and recent identity system trends, we present an overview of the 48 national identity programs, including technical features (such as whether physical identities incorporate an electronic component or are embedded with biometric features), implementation status, population enrollment strategies, and coverage. We next review evidence of implementation challenges around accountability, privacy, data management, enrollment, coverage, cost, and harmonization of identity programs. Finally, we present the functional applications of national identity programs, reporting how these programs are linked with services in finance, health, agriculture, elections, and other areas, and analyzing whether particular identity program characteristics are associated with functional applications.
This report provides a summary of findings from six Financial Inclusion Insights (FII) data analysis reports conducted by various agencies for the Bill & Melinda Gates Foundation (BMGF). These reports investigate barriers to financial inclusion and use of digital financial services (DFS) in Bangladesh, India, Kenya, Nigeria, Pakistan, Tanzania, and Uganda. We compile comparable gender-specific statistics, summarize the authors’ findings to determine commonalities and differences across countries, and highlight gender-specific conclusions and recommendations provided in the studies.
This brief reviews the evidence of realized yield gains by smallholder farmers attributable to the use of high-quality seed and/or improved seed varieties. Our analysis suggests that in most cases, use of improved varieties and/or quality seed is associated with modest yield increases. In the sample of 395 trials reviewed, positive yield changes accompanied the use of improved variety or quality seed, on average, in 10 out of 12 crops, with rice and cassava as the two exceptions.